4Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med, 2007,176:532-555.
5Agusti AG. COPD, a multicomponent disease: implications for management. Respir Med, 2005,99:670-682.
6Hogg JC,Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Eng J Med, 2004,350:2645-2653.
7Parr DG, White AJ, Bayley DL, et al. Inflammation in sputum relates to progression of disease in subjects with COPD: a prospective descriptive study. Respir Res, 2006,7 : 136.
8Johnson M. Interactions between corticosteroids and beta2-agonists in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc, 2004,1:200-206.
9Adcock IM, Maneechotesuwan K, Usmani O. Molecular interactions between glucocorticosteroids and long-acting beta2- agonists. J Allergy Clin Immunol, 2002, 110 (6 Suppl) : S261- S268.
10Lindberg A, Szalai Z, Pullerits T, et al. Fast onset of effect of budesanide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction. Respirology, 2007, 12: 732- 739.
